The latest healthcare innovations, including a major corporate reorganisation, preventative diagnostics and a dedicated EHR platform for eating disorder care.
Androlabs reorganises to expand global men’s health pharma
Global men’s health pharmaceutical company Androlabs has streamlined operations, expanded its product portfolio, and broadened international market access.
The reorganisation involves divesting sister company Simple Pharma from the group. All marketing authorisations for Androlabs’ primary prescription brands – Testavan and Vitaros – are being transferred to dedicated Androlabs legal entities. Global distribution will be managed via the newly established Labs Distribution, bringing teams from Simple Pharma and Androlabs together under a single unified corporate architecture.
As part of the changes, parent company Tithonia Group has carved out The Simple Pharma Company, which has been acquired by Tamrisa Access to operate independently. The restructuring builds on five years of commercial growth following Androlabs’ initial acquisition of Testavan and Vitaros from Ferring Pharmaceuticals, while supporting recent line extensions such as a new UK marketing authorisation for a Testavan 4.6 mg/actuation presentation.
“Building Androlabs and Simple Pharma over the last five years has been about proving that there is a different way to build a pharmaceutical company,” said Charlie Bryant, chief executive and co-founder of Androlabs. “We have proved the model – now we want to build on it.”

Ultimate Performance partners with Emerald
Personal training organisation Ultimate Performance has partnered with CQC-registered preventative healthcare platform Emerald to offer comprehensive health screening and diagnostic tools to its gym members.
Through the agreement, Ultimate Performance members will receive access to Emerald membership for 12 months. The platform delivers blood testing analysing 124 distinct biomarkers – spanning metabolic, cardiovascular, hormonal, inflammation and organ function markers – and combines lab results with wearable device metrics and medical history. Each member is matched with a GP who provides continuous clinical oversight, writes prescriptions, and manages formal referrals into private or NHS care pathways where clinically indicated.
The diagnostics will be used in Ultimate Performance’s 12 UK locations to allow personal trainers to tailor strength training and nutrition plans based on objective biomarker data.
“Emerald gives you a detailed snapshot of your health at that moment in time, while Ultimate Performance gives you access to world-class personal trainers who can help you turn that information into action through structured strength training and accountability,” said Sean Murphy, chief personal trainer at Ultimate Performance.
Qyire expands eating disorder care
Health tech startup Qyire has launched an electronic health record (EHR) platform built to unify fragmented clinical documentation and physical health monitoring within eating disorder services.
Because effective eating disorder treatment relies on a multidisciplinary team spanning psychiatrists, psychologists, dietitians and nursing staff, care documentation is traditionally split across disparate systems. Qyire centralises referrals, assessments, care plans, appointment notes and outcome measures into a single shared record.
Designed around Medical Emergencies in Eating Disorders (MEED) guidance, the software features automated MEED scoring and real-time physical health tracking. Designed for use across mental health hospitals, outpatient clinics, private practices and community care teams, Qyire is currently engaged in pilot discussions with independent and residential providers across the UK, Australia and New Zealand.
“Often a patient’s care records are split across separate notes and systems. A dietitian and a doctor can each hold part of the picture, and the team has to piece it together before it can agree the next step,” said Laetitia Beaujard-Ramoo, chief executive officer of Qyire. “We designed Qyire so the whole team works from one record, built to the MEED guidance. Independent and residential providers need a record designed for the way specialist teams work. Qyire gives them that.”

Hyland releases enterprise digital pathology platform
Enterprise content and imaging software provider Hyland has launched Hyland Digital Pathology, an enterprise-grade solution powered by Tribun Health’s CaloPix platform, designed to consolidate digital pathology alongside radiology and cardiology within a single governed architecture.
The software integrates Tribun Health’s CaloPix Image Management System – which holds regulatory clearances including FDA clearance, CE-Marking, Health Canada licensing and ARTG inclusion as a Class 1 software IVD medical device – into Hyland’s Acuo Vendor-Neutral Archive (VNA) and NilRead universal viewer infrastructure.
Built on open standards including DICOM compatibility and LIS/EMR connectivity, the vendor-neutral platform enables primary digital diagnosis, telepathology and AI-assisted analysis while allowing multidisciplinary care teams to access pathology data alongside radiology and cardiology studies within a single interface.
“Pathology belongs at the core of an enterprise medical imaging strategy,” said Vinitha Ramnathan, general manager of healthcare product management at Hyland. “We’re helping health systems move beyond isolated workflows to connect pathology with radiology and cardiology on a scalable, governed imaging foundation. This gives pathologists the tools to collaborate across locations and brings critical diagnostic information closer to the teams making care decisions.”
GenesisCare UK expands breast cancer treatment
Cancer care provider GenesisCare UK has partnered with medical imaging software innovator Lunit to introduce the Lunit INSIGHT Breast Suite AI software into clinical practice. It is the first UK-based healthcare provider to deploy the technology.
The CE-marked and FDA-cleared software assists radiologists by performing automatic breast density scoring and AI-driven lesion detection, pinpointing subtle abnormalities such as masses, calcifications and architectural distortions. The provider says that real-world clinical evaluations of the platform have demonstrated a 13.8% increase in breast cancer detection rates alongside reductions in recall rates and false positives.
GenesisCare says that AI will act as an analytical decision-support layer. The automated breast density scoring provides a standardised measure of dense tissue – a key factor that can obscure malignancies and increase overall breast cancer risk – enabling clinicians to personalise screening and determine whether supplementary imaging is required.
“Mammograms can reveal very early signs of breast cancer, but some changes are extremely small, subtle or difficult to distinguish, particularly in dense breast tissue,” said Fleur Kilburn-Toppin, specialist advisor for breast radiology at GenesisCare. “Automatic breast density scoring gives us additional information to inform assessment, while AI-supported lesion detection highlights suspicious areas for closer review. Together, these tools support our interpretation of mammograms and our ability to detect cancer earlier… Improving accuracy can help reduce unnecessary callbacks and biopsies, which can cause significant stress and worry for patients and their families.”

St John & St Elizabeth Hospital introduces da Vinci Xi robotic surgery
London’s St John & St Elizabeth Hospital has introduced robotic-assisted surgery at its St John’s Wood campus via an Intuitive da Vinci Xi surgical system.
The deployment will support minimally invasive, complex procedures across urology, gynaecology, general and colorectal surgery. Using 3D high-definition visualisation and wristed instrumentation, the console translates surgeon hand movements in real time to enable complex interventions through small incisions. The technology builds on the hospital’s recent strategic partnership with Icon Cancer Centre to construct a dedicated, purpose-built cancer facility on the same site, establishing integrated robotic surgical and radiotherapy services set to open fully from next year.
“This is another statement of intent,” said Simon James, chief executive of St John & St Elizabeth Hospital. “Robotic surgery in our theatres and a new cancer centre with Icon demonstrates the hospital we are building, and the level of care we want to offer our community.”
UK Health Security Agency appoints Sign Solutions
British Sign Language (BSL) provider Sign Solutions has been appointed by the UK Health Security Agency (UKHSA) to supply on-demand video relay services via its InterpretersLive! platform.
Deaf BSL users will have direct, real-time access to official UKHSA communications, guidance, and emergency health services during public health incidents. The InterpretersLive! platform connects users with NRCPD-registered BSL interpreters to facilitate instant communication between deaf and hearing individuals across digital and phone channels.
The UKHSA is responsible for public health protection, disease surveillance and emergency response across England.
“The pandemic showed how important it is for deaf people to receive timely public health information in BSL,” said Clare Vale, managing director of Sign Solutions. “If a future emergency occurs, InterpretersLive! will help Deaf BSL users access UKHSA information and services quickly and directly. This appointment recognises the important role that video relay services can play in making official communications accessible.”

FemTick launches to help women’s health sector
Global advocacy group CensHERship has launched FemTick, a world-first accreditation scheme designed to recognise financial, legal and commercial service providers supporting the growth of the women’s health economy.
The initiative addresses widespread structural bias and operational friction faced by women’s health and femtech startups when accessing fundamental business infrastructure. FemTick establishes a dedicated trust standard and directory for verified, bias-free service providers.
Nine founding commercial partners across banking, law, insurance, accounting and risk management have joined the framework to support the sector’s scaling. The founding cohort includes law firm Mills & Reeve alongside HSBC Innovation Banking, Tokio Marine Kiln, Commerce, Withum, Practicus, Novabook, LT PR and Communia. The partners will work alongside FemTick to shape the accreditation framework as the global femtech market scales toward an estimated £450 billion valuation by 2030.
“Women’s health is one of the largest and fastest-growing opportunities in global healthcare, yet the infrastructure supporting the sector has not always evolved at the same pace,” said Clio Wood, co-founder and chief executive of CensHERship. “Our founding partners for FemTick recognise the scale of the opportunity and are among the first movers helping build the infrastructure needed for the sector to scale.”



